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Hormonally regulated breast and prostate cancers are the most common cause of cancer
in females and males respectively. FoxA1 acts as a pioneer factor for both androgen recep-
tor (AR) and estrogen receptor-α (ER), dictating the binding location, and therefore function
of these transcription factors. It is an essential protein for the transcriptional activity of
both ER and AR, yet it has distinct roles with the two different nuclear receptors. In both
malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant
and metastatic disease. Due to this key role in mediating ER and AR function, FoxA1 is not
only an attractive therapeutic target but could potentially function as a novel biomarker.
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Breast and prostate cancer are hormonally fueled cancers driven
by the sex steroid hormones estrogen and androgen, that activate
their respective nuclear receptors estrogen receptor (ER) or andro-
gen receptor (AR). These nuclear receptors do not function alone
but with a plethora of other transcription factors and co-factors,
which aid ER and AR to elicit a pro-tumorigenic gene expression
program. FoxA1 is an interacting partner of both AR and ER where
it plays a crucial role in the development and progression of breast
and prostate cancer.
FoxA1 is one of three members of the FoxA family, a subset of
the forkhead family of transcription factors which play vital roles
in development (reviewed in Hannenhalli and Kaestner, 2009).
Initially FoxA1 was discovered for its role in liver development
(Costa et al., 1989) but has also been implicated in the devel-
opment of a number of other organs (Bernardo and Keri, 2012)
including the androgen and estrogen regulated tissues of the breast
and prostate. From observations in the FoxA1−/− mice, normal
mammary duct or prostate rudiment develops during embryoge-
nesis but pubertal ductal morphogenesis does not occur in either
organ (Gao et al., 2005; Bernardo et al., 2010). As is often the case,
cancer mirrors development and FoxA1 plays a pivotal part in the
development of breast and prostate cancer. This perspective aims
to highlight the recent discoveries in the interplay of FoxA1 with
AR and ER in cancer and the potential clinical implications of
these interactions.
FoxA1 FACILITATES CHROMATIN ACCESSIBILITY FOR ER
AND AR AT CELL TYPE SPECIFIC LOCATIONS
The first evidence of an interaction between ER and FoxA1 was
shown at the estrogen regulated Vitellogenin B1 gene promoter
after microinjection of the two proteins into Xenopus laevis oocytes
(Robyr et al., 2000). However it was not until the advent of high-
throughput technologies, that the elucidation of a wide spread
association of FoxA1 with hormone nuclear receptors occurred.
The first large scale assessment of ER–chromatin interactions
involved chromatin immunoprecipitation (ChIP) enrichment of
DNA bound by ER, coupled to microarrays containing all the
non-repetitive regions of chromosome 21 and 22 (Carroll et al.,
2005). From this initial experiment two key finding were made
(a) ER mainly binds significant distances from the transcriptional
start sites of the coding genes it regulates (regions termed dis-
tal enhancers) and (b) motif analysis of the DNA under the ER
binding sites revealed EREs (estrogen responsive elements) and
motifs for forkhead factors. With improvements in technology,
from genome wide microarrays through to ChIP coupled to high-
throughput sequencing (ChIP-seq), these two facts have held up
in numerous cell line studies (Laganiere et al., 2005; Carroll et al.,
2006; Ross-Innes et al., 2010; Hurtado et al., 2011), demonstrat-
ing the importance of the initial observation (Carroll et al., 2005).
The first comprehensive ER ChIP-seq in primary breast cancer
tissue has just been completed and forkhead motifs were again
enriched in the ER binding events, particularly in binding events
that occurred in breast cancer patients with a poor clinical out-
come (Ross-Innes et al., 2012). An interaction between AR and
FoxA1 was first shown at the promoter of the androgen regulated
genes probasin and PSA (Gao et al., 2003). ChIP-chip and ChIP-
seq of AR in LNCaP (Wang et al., 2007, 2009; Robinson et al., 2011;
Tan et al., 2012) and C4-2B (Jia et al., 2008) cell lines confirmed
the presence of forkhead motifs in AR binding events. The link
between AR and FoxA1 has been reinforced by FoxA1 ChIP-seq
experiments, which have shown that ∼50% ER binding sites and
∼70% AR binding events occur at regions also co-occupied by
FoxA1 (Hurtado et al., 2011; Robinson et al., 2011; Sahu et al.,
2011).
FoxA1 functions as a “pioneer factor” for transcription factors
such as AR and ER, engaging with condensed chromatin and facil-
itating the association of other factors (recently reviewed in Zaret
and Carroll, 2011). FoxA1 and the other FoxA family members
have a so-called “winged helix” structure, which makes them per-
fectly adapted to this role. They perch in the major groove of DNA
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through an alpha helix domain with two loops, like wings, which
make additional site specific contacts with the DNA (Clark et al.,
1993) in a structure similar to that of the linker Histone H1. When
FoxA1 is silenced in the ER+ breast cancer cell line MCF7, there is
a significant loss in global chromatin accessibility coupled with a
concurrent loss of ER binding at more than 90% of all ER binding
events (Hurtado et al., 2011). This result emphasizes how essential
FoxA1 is for ER to function in breast cancer. As will be discussed
later, the interaction between AR and FoxA1 is more complicated
and does not result in a simple loss of AR binding after silencing
of FoxA1.
Androgen receptor and ER only bind to a very small subset of
locations in the genome where their canonical motifs (ARE and
EREs) occur, indicating that other factors must constrain their
positioning. FoxA1 appears to provide cell type specificity for ER
and AR binding and therefore, FoxA1 ultimately dictates the estro-
gen and androgen gene targets. Cell type specific FoxA1 sites in
breast and prostate cancer cell lines often overlap with the dri-
ving nuclear receptor and are enriched proximal to genes that are
expressed in that cancer type (Lupien et al., 2008; Eeckhoute et al.,
2009). In fact, it is possible to predict a functional ER binding
site by the presence of FoxA1 binding in conjunction with an ERE
motif and the histone modification H3K4me1 (Joseph et al., 2010)
which underscores the importance of FoxA1. That said there are
many FoxA1 sites that do not recruit a nuclear receptor and equally
a number of AR and ER sites where there is no FoxA1 binding. As
such, although FoxA1 is a required parameter for ER binding,
alone it is not sufficient and additional collaborating factors help
contribute to functional enhancer elements.
Approximately 50% of FoxA1 sites are shared between dif-
ferent cell lines (Hurtado et al., 2011; Robinson et al., 2011); a
specific binding pattern that appears to be influenced by the his-
tone landscape. FoxA1 binds preferentially to the active histone
marks H3K4me1 and H3K4me2 and less at regions possessing the
H3K9me2 repressive mark (Lupien et al., 2008). The part that
FoxA1 plays in the reading, maintenance, or creation of these
chromatin modifications is still undetermined. However there is
evidence to suggest that FoxA1 may be actively involved in the
maintenance of these marks, since forced FoxA1 expression in
FoxA1 negative MDA-MB-231 breast cancer cells results in binding
at regions that subsequently acquire H3K4me2 marks (Sérandour
et al., 2011). FoxA1 binding may also be influenced by DNA methy-
lation, since it is enriched at regions of low methylation and FoxA1
binding occurs before differentiation induced demethylation in
mouse pluripotent P19 cells (Sérandour et al., 2011).
FoxA1 HAS THE ABILITY TO REPROGRAM THE BINDING OF
AR AND ER
As FoxA1 demarks the chromatin locations where AR binds and
its removal results in loss of ER binding, one would presume that
AR binding in the prostate would be lost in the absence of FoxA1.
However, two groups showed that loss of FoxA1 results in redis-
tribution of AR and initiation of a new transcriptional program
(Sahu et al., 2011; Wang et al., 2011). Both studies used siRNA
to deplete FoxA1 in LNCaP prostate cancer cells, then conducted
AR ChIP-seq and compared the results to the parental cells. The
results are markedly similar and show that loss of FoxA1 results
in loss of ∼50% AR binding events (FoxA1 dependent), with the
remaining 50% of AR sites still present, independently of FoxA1.
Moreover, in the absence of FoxA1, there is a pronounced gain in
novel AR binding events, resulting in threefold more AR binding
in the absence of FoxA1. This unexpected finding was validated
in another prostate cancer cell line, VCaP, and for another nuclear
receptor, GR (Sahu et al., 2011). Gene expression changes and the
production of eRNAs (small RNAs produced at active enhancers)
echoed the same changes seen in genomic binding events and
the new/lost binding events were enriched near these differen-
tially expressed regions. It appears that FoxA1 normally represses
AR binding at some locations, but the lack of FoxA1 binding
at the regions where AR is reprogrammed suggests an indirect
trans-repression mechanism (Wang et al., 2011).
The loss of FoxA1 in LNCaPs was accompanied by little change
in the histone marks, H3K4me1 (Wang et al., 2011), H3K4me2
(Sahu et al., 2011), or H3K27Ac (Wang et al., 2011). In fact, 50%
of the AR gained events did not have DNase I hypersensitivity (a
marker for open chromatin; Sahu et al., 2011) and H2A.Z ChIP-
seq suggested that there was no nucleosome remodeling at these
new AR events (Wang et al., 2011). This leads to the question of
how AR is able to bind to these regions of apparently less accessible
chromatin yet still manage to elicit a change in gene expression.
It hints toward a non-classical method of AR binding and activ-
ity. One explanation for this phenomenon is that FoxA1 may be
required to maintain the structure of the chromatin in a certain
manner, forcing AR to bind to specific sites and simultaneously
preventing binding to numerous other regions, a hypothesis sup-
ported by the gain of the looping protein Med12 binding at the
new sites (Wang et al., 2011). Alternatively another protein could
be acting in place of FoxA1 to maintain the mark and recruit AR
to its reprogrammed locations.
In contrast to AR in prostate cancer cells, it is the over-
expression of FoxA1 that induces redistribution of ER. By forcing
FoxA1 expression in U2OS-ER osteosarcoma cells, the ER binding
profile changes from bone cancer-specific sites to locations nor-
mally observed in breast cancer (Hurtado et al., 2011). Similarly,
the ectopic expression of ER, FoxA1, and an additional interact-
ing transcription factor GATA3, can induce hormone responsive
growth in the ER− breast cancer cell lines MDA-MB-231 and BT-
549 (Kong et al., 2011). In this scenario, each factor had no effect in
isolation, illustrating a clear co-operative interaction, which must
occur for effective ER transcriptional response. This reprogram-
ming ability highlights the complexity of FoxA1’s function as an
initiation factor for ER yet it harbors some repressive properties
in its interactions with AR as illustrated in Figure 1.
FoxA1 HAS A VITAL ROLE IN MOLECULAR APOCRINE
(ER−AR+) BREAST CANCER
Estrogen receptor negative (ER−) breast cancers constitute
approximately one-third of all cases and were historically thought
to be hormonally unresponsive. However a number of studies have
identified a subset of ER− breast cancers which are driven by AR.
These tumors have a more luminal like expression profile, typi-
cal to ER+ tumors, and all express AR which seems to act as a
proxy for the lack of ER (Farmer et al., 2005; Doane et al., 2006;
Teschendorff et al., 2007). This ER− breast cancer subtype has
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FIGURE 1 | Loss of FoxA1 has disparate effects on nuclear receptor
binding. FoxA1 acts as a pioneer factor for ER and AR allowing the
nuclear receptors to make targeted contacts with specific genomic
regions which induce a transcriptional response. The loss of FoxA1
results in condensation of the chromatin so ER and AR can no longer
bind to DNA at specific locations. However AR still appears to be able to
bind in an unorthodox manner, without nucleosome redistribution or
active histone marks. This may be due to changes in chromatin
architecture and the development of new loops or through an alternate
transcription factor.
been validated in additional studies, each group coining their own
name but for this review we will refer to them as molecular apoc-
rine. The ER−AR+ breast cancer cell line MDA-MB-453 has a
comparable gene expression profile to that of molecular apocrine
tumors and is often used as a representative model. AR has been
shown to be necessary for growth of MDA-MB-453 cells in vitro
(Doane et al., 2006), in three-dimensional culture (Robinson et al.,
2011), and in mouse xenografts (Ni et al., 2011). To understand the
function of AR, the Brown lab and our lab conducted AR ChIP-seq
in MDA-MB-453 cells (Ni et al., 2011; Robinson et al., 2011). Due
to differences in experimental design, methodology, and sequenc-
ing platform, there was a 10-fold difference in the absolute number
of AR binding events between the two datasets, but despite this dis-
crepancy, motif analysis in both cases showed a strong association
with forkhead motifs at the summit of the AR peaks.
FoxA1 is highly expressed in molecular apocrine tumors
(Doane et al., 2006; Ni et al., 2011) and a comparison of genome
wide FoxA1 occupancy in our study found an unprecedented level
of concordance between AR and FoxA1 binding: 98% overlap
(Robinson et al., 2011). Even though Ni et al. saw a lower level
of overlap between AR and FoxA1 binding (37%), these co-bound
sites were much more likely to be near testosterone regulated genes
(p < 5.3 × 10−20) than AR unique sites (p < 0.011) implying that
these are the more functional AR sites. We found that AR’s genomic
locations were more similar to ER binding events in MCF7 cells
than AR binding in the prostate cancer cell line LNCaP (Robinson
et al., 2011). FoxA1 binding was shown to have a cell type specific
pattern in MDA-MB-453 cells and therefore could be directing
AR to these regions normally occupied by ER. Additionally, FoxA1
was required for expression of the growth promoting gene expres-
sion profile commonly seen in molecular apocrine breast cancer
and growth of the cells. Since AR has a growth inhibitory func-
tion in ER+ breast cancer cells, but a growth promoting effect in
ER− molecular apocrine breast cancer cells (Birrell et al., 1995), it
would be of interest to map binding of AR in a ER+AR+ context
to assess how the presence of ER influences AR binding on a global
scale and how FoxA1 is involved in this cross-talk.
FoxA1 HAS OPPOSING PREDICTIVE POWER IN BREAST AND
PROSTATE CANCER
FoxA1 has been repeatedly found to be a marker for good prog-
nosis in ER+ breast cancer and it is an independent marker for
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recurrence free survival and overall survival (Badve et al., 2007).
Initial studies suggest that it may have better prognostic signifi-
cance than progesterone receptor, a classic marker for breast cancer
outcome (Badve et al., 2007) or the proliferation marker Ki67
(Hisamatsu et al., 2011). Breast cancer is a very heterogeneous
disease and FoxA1 may be useful as a biomarker for the strat-
ification of patients with ER+ HER2− disease, a subset which
currently suffers from over-treatment. Tumors within this cohort
that have high FoxA1 levels respond equally well with or with-
out chemotherapy (Hisamatsu et al., 2011) and a study with a
large cohort of 4444 patients treated with tamoxifen showed that
FoxA1 was predictive of response and therefore has the potential to
identify a subgroup who could be treated less aggressively (Mehta
et al., 2012).
In prostate cancer however, it appears that the opposite is true
and that high FoxA1 is a predictor of poor prognosis. Two large
scale tissue microarray (TMA) studies have been carried out in
the last year assessing FoxA1 expression across 288 and 350 cases
respectively (Sahu et al., 2011; Gerhardt et al., 2012). Sahu et al.
(2011) noted a strong correlation of FoxA1 staining with AR levels
(r = 0.72, p < 0.0001) and high FoxA1 staining was a marker of
shorter time to prostate cancer-specific death (hazard ratio = 2.89,
p = 0.04). These discoveries were reproduced by a separate study
(Gerhardt et al., 2012), which also found that patients with high
FoxA1 levels have shorter time to biochemical recurrence, a com-
mon indicator of relapse, however, FoxA1 was not an independent
prognostic marker. Interestingly high FoxA1 staining was observed
in patients who have become resistant to hormonal therapy (cas-
trate resistant prostate cancer – CRPC) and FoxA1 positivity was
seen in 32 out of 39 lymph node and distant metastases. An inde-
pendent study also found FoxA1 to be highly expressed in 90% of
prostate cancer metastases (Jain et al., 2011), an observation that
FIGURE 2 |The clinical paradox of FoxA1 in relation to breast and
prostate cancer. FoxA1 is a good prognostic marker in ER+ breast
cancer yet in prostate cancer is a marker of poor outcome as indicated
by the hypothetical survival curves. This may be due to differences in the
hormonally responsive pathways activated by FoxA1. However for
end-stage disease for both breast and prostate cancer, there is increased
expression of FoxA1 suggesting dependence on the nuclear receptor
complex.
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has also been seen in breast cancer metastases (Ross-Innes et al.,
2012).
Clinical observations again highlight that FoxA1 interacts dif-
ferently with ER and AR in primary cancer and are summarized
in our schematics in Figure 2. With regard to ER in breast can-
cer, FoxA1 is a marker for good outcome, possibly because it
enables a functional ER complex, resulting in increased sensi-
tivity to ER antagonists, such as tamoxifen. Concordantly, it has
been shown that FoxA1 is essential for tamoxifen to functional
(Hurtado et al., 2011). However, in the case of prostate cancer,
higher levels of FoxA1 are a marker for poor outcome, which may
in part be due to the fact that FoxA1 correlates with AR levels.
Increased AR is a poor prognosis marker in prostate cancer (Ger-
hardt et al., 2012) and amplification of the AR gene is one of
the many ways that prostate cancer circumvents hormonal ther-
apies (Brown et al., 2002; Edwards et al., 2003; Ford III et al.,
2003). Since high FoxA1 is observed in both breast and prostate
metastases, we hypothesize that there is a shared dependence on
this transcription factor at secondary sites of breast and prostate
metastasis. Furthermore, the increase of FoxA1 in CRPC patients
(Gerhardt et al., 2012) is particularly interesting, since it may hint
toward a novel mechanism for the reactivation of AR in these
hormone deprived tumors. An alternate hypothesis, independent
of AR, has been postulated in a LNCaP model of CRPC, where
FoxA1 can drive G1–S phase transition through recruitment of
MYBL2 or CREB1 to the Cyclin E2 and E2F1 genes (Zhang et al.,
2011).
FoxA1 IS A KEY TARGET IN BREAST AND PROSTATE CANCER
Given the fact that FoxA1 is required for the growth of ER+ breast
cancer cell lines (Laganiere et al., 2005), ER−AR+ breast cancer
cell lines (Robinson et al., 2011), and prostate cancer cell lines
(Zhang et al., 2011), FoxA1 constitutes an attractive therapeutic
target in a range of different hormone dependent cancers. In par-
ticular, it may be a good second line therapy as FoxA1 is required
for growth of drug resistant breast and prostate cancer cell lines
(Hurtado et al., 2011; Zhang et al., 2011). Transcription factors
are notoriously difficult to target, in part due to their ubiquitous
nature, a problem which is partially relieved by the observation
that FoxA1 is only expressed in a few adult tissues. Furthermore,
the binding and transcriptional activity of another forkhead fam-
ily member, FOXM1, has been inhibited by the natural product
thiostrepton (Hegde et al., 2011) which raises the possibility of
finding compounds that selectively target FoxA1.
CONCLUSION
FoxA1 is a critical mediator of the function of both AR and ER in
the context of breast and prostate cancer, from initial tumorige-
nesis through to hormone resistant, metastatic disease. Although
FoxA1 appears to be a critical determinant of ER and AR bind-
ing and function, it does not work alone, but in concert with a
host of other AR and ER interacting partners, that are required
to make a fully functional transcriptional complex capable of
responding to hormonal activation. That said, FoxA1 is a fac-
tor that appears to play a critical and central role in mediating
ER and AR interactions with chromatin. In the future, further
exploration into the potential of FoxA1 in the clinic as either
a drug target or a new biomarker may prove to be clinically
beneficial.
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